Minakem, a contract manufacturing company, specialized in custom development and manufacturing of building blocks, intermediates and Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, received a €14.5M ($18M) investment from parent company Minafin.
The company will use the funds to continue to extend its manufacturing capacity at its Dunkirk site in France. It will enable Minakem to set up a new production line, increasing production capacity by 28m3.
In parallel, existing production assets are being upgraded in order to increase flexibility. This will free up an additional 26m3 production volume. In total, the production volume at the Dunkirk site will increase by 54m3 to a total capacity of 148m3.
Led by Thierry van Nieuwenhove, CEO, Minakem is a fine chemical company with operations at three facilities located in Dunkirk (FR), Beuvry la Foret (FR) and Louvain-la-Neuve (BE) and expertise in complex multi-step synthesis, pressure chemistry, chiral synthesis, halogenation chemistry, steroid chemistry and ‘prazole’ chemistry.
The company has more than 450 employees.